1Olaussen K A,Dunant A, Fouret P, et al. DNA repair by ERCC1 in non- small-cell lung cancer and cisplatinbased adjuvant chemotherapy [J]. N Engl J Med, 2006,355(10) :983-991.
2Cobo M, Isla D, Massuit B, et al. Customizing cisplatin based quantitative excision repair complementing 1 mRNA : a phase III trial in non-small-cell lung cancer[J].J Clin Oncol, 2007,25 (19):2747- 2754.
3Rosell R, Danenberg K D, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients [J]. Clin Cancer Res, 2004, 10(4) : 1318-1325.
4Souglakos J, Boukovinas I,Taxon M, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine[J].Br J Cancer, 2008,98(10) : 1710-1715.
5Zhou C, Zhou S, Zhang L. RRMland BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisptatin-based chemotherapy [J]. J Clin Oncol, 2009, 27 : $8097.
6Sere P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel [ J ]. Mol Cancer Ther, 2005,4(12):2001-2007.
7Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and Class III beta-tubulin in non-small cell lung cancer patients treated with carboplafin and paclitaxel [J]. Lung Cancer, 2009, 64(3) :326-333.
8Popat S, Matakidou A, Houlston R S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and metaanalysis [J]. J Clin Oncol, 2004,22(3),529- 536.
9Garcia V, Garcia J M, Pena C, et al. Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer:prognostic potential [J], Clin Cancer Res, 2006,12(7) :2095- 2100.
10Lecomte T, Ferraz J M, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5- FU-based chemotherapy [J]. Clin Cancer Res, 2004,10 (17):5880- 5888.
2Demetri GD,Chawla SP,Von Mehren M,et al.Efficacy andsafety of trabectedin in patients with advanced or metastatic li-posarcoma or leiomyosarcoma after failure of prior anthracy-clines and ifosfamide:results of a randomized phase II study oftwo different schedules[J].J Clin Oncol,2009,27(25):4188.
